1. Home
  2. CERO vs AMBO Comparison

CERO vs AMBO Comparison

Compare CERO & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • AMBO
  • Stock Information
  • Founded
  • CERO 2017
  • AMBO 2000
  • Country
  • CERO United States
  • AMBO United States
  • Employees
  • CERO N/A
  • AMBO N/A
  • Industry
  • CERO
  • AMBO Other Consumer Services
  • Sector
  • CERO
  • AMBO Real Estate
  • Exchange
  • CERO Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • CERO 3.5M
  • AMBO 8.8M
  • IPO Year
  • CERO N/A
  • AMBO 2010
  • Fundamental
  • Price
  • CERO $9.79
  • AMBO $2.59
  • Analyst Decision
  • CERO Strong Buy
  • AMBO
  • Analyst Count
  • CERO 2
  • AMBO 0
  • Target Price
  • CERO $45.00
  • AMBO N/A
  • AVG Volume (30 Days)
  • CERO 3.3M
  • AMBO 6.7K
  • Earning Date
  • CERO 08-13-2025
  • AMBO 01-01-0001
  • Dividend Yield
  • CERO N/A
  • AMBO N/A
  • EPS Growth
  • CERO N/A
  • AMBO N/A
  • EPS
  • CERO N/A
  • AMBO 0.11
  • Revenue
  • CERO N/A
  • AMBO $9,392,000.00
  • Revenue This Year
  • CERO N/A
  • AMBO N/A
  • Revenue Next Year
  • CERO N/A
  • AMBO N/A
  • P/E Ratio
  • CERO N/A
  • AMBO $23.33
  • Revenue Growth
  • CERO N/A
  • AMBO 2.50
  • 52 Week Low
  • CERO $6.71
  • AMBO $1.00
  • 52 Week High
  • CERO $895.40
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • CERO 50.09
  • AMBO 44.84
  • Support Level
  • CERO $8.12
  • AMBO $2.20
  • Resistance Level
  • CERO $13.14
  • AMBO $2.82
  • Average True Range (ATR)
  • CERO 2.83
  • AMBO 0.19
  • MACD
  • CERO 0.39
  • AMBO -0.01
  • Stochastic Oscillator
  • CERO 19.58
  • AMBO 54.44

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

Share on Social Networks: